Direkt zum Inhalt
Merck
  • Characterization of the new AmpC β-lactamase FOX-8 reveals a single mutation, Phe313Leu, located in the R2 loop that affects ceftazidime hydrolysis.

Characterization of the new AmpC β-lactamase FOX-8 reveals a single mutation, Phe313Leu, located in the R2 loop that affects ceftazidime hydrolysis.

Antimicrobial agents and chemotherapy (2013-07-24)
Francisco José Pérez-Llarena, Frédéric Kerff, Laura Zamorano, María Carmen Fernández, Maria Luz Nuñez, Elisenda Miró, Antonio Oliver, Ferran Navarro, Germán Bou
ZUSAMMENFASSUNG

A novel class C β-lactamase (FOX-8) was isolated from a clinical strain of Escherichia coli. The FOX-8 enzyme possessed a unique substitution (Phe313Leu) compared to FOX-3. Isogenic E. coli strains carrying FOX-8 showed an 8-fold reduction in resistance to ceftazidime relative to FOX-3. In a kinetic analysis, FOX-8 displayed a 33-fold reduction in kcat/Km for ceftazidime compared to FOX-3. In the FOX family of β-lactamases, the Phe313 residue located in the R2 loop affects ceftazidime hydrolysis and alters the phenotype of E. coli strains carrying this variant.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

USP
Ceftazidim Pentahydrat, United States Pharmacopeia (USP) Reference Standard
Ceftazidim, European Pharmacopoeia (EP) Reference Standard
Ceftazidim für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard